Psychedelic medicine (New Rochelle, N.Y.)最新文献

{"title":"A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions","authors":"William Brennan, Alex R. Kelman, Alexander B. Belser","doi":"10.1089/psymed.2023.0007","DOIUrl":"https://doi.org/10.1089/psymed.2023.0007","url":null,"abstract":"Background: Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychosocial interventions (PIs) in clinical trials of psychedelic treatment due in part to deficiencies in reporting practices found in the existing literature. These PI include non-drug support or interventions provided by psychotherapists or facilitators during all phases of treatment, sometimes called “psychological support,” “monitoring,” “psychedelic-assisted therapy,” or “psychedelic-assisted psychotherapy.” A brief review of recent research, historical studies, safety considerations, and participant perspectives suggests that PI has a substantive and critical impact on treatment outcomes. Methods: This systematic review examines the reporting practices on PI in published clinical trial results. The review employs a search of PubMed/Medline and PSYCinfo databases to identify relevant articles. It includes quantitative clinical studies treating patients with psychiatric indications using classic psychedelics (psilocybin, LSD, DMT, ayahuasca) or empathogenic drugs (MDMA) since 2000. The analytic approach follows a modified version of assessment items based on CONSORT extension statement and TIDieR checklist. Results: Thirty-three published psychedelic clinical trials met criteria. The review reveals that many published reports on psychedelic clinical trials did not report basic aspects of the intervention: 33% did not report the number of sessions, 45% did not report the duration of sessions, 42% did not report provider credentials, 52% did not report whether their intervention used a therapy manual, 64% did not reference a manual that was available to readers, and 82% did not report that they assessed treatment fidelity. A comparison with non-psychedelic trials shows that psychedelic trial reports underreport on key items related to PI. Discussion: The study highlights the problems of underreporting and the importance of improving reporting practices regarding PI in psychedelic clinical trials to enhance research standardization and improve treatment outcomes. Recommendations for improving reporting practices are provided.","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"127 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136034506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review of Study Design and Placebo Controls in Psychedelic Research","authors":"Alexander Wen, Nikhita Singhal, Brett D.M. Jones, Richard J. Zeifman, Shobha Mehta, Mohammad A. Shenasa, Daniel M. Blumberger, Zafiris J. Daskalakis, Cory R. Weissman","doi":"10.1089/psymed.2023.0028","DOIUrl":"https://doi.org/10.1089/psymed.2023.0028","url":null,"abstract":"Introduction: Effective blinding is especially challenging in randomized controlled trials (RCTs) involving psychedelics due to the inherent alterations in consciousness that these compounds induce. In this systematic review and exploratory analysis, we aim at synthesizing the methodologies used in RCTs involving classic psychedelics and identify procedures that can help minimize unblinding and bias. Methods: We completed a literature search that included prospective RCTs published between 1963 and January 2023, in which participants were randomized to receive either a classic psychedelic or placebo. Results: A total of 1402 papers were included in the initial search. After eligibility criteria were applied, 50 papers from 48 clinical trials were included. Most studies were double blinded (n = 34), used a within-subjects design (n = 32 studies), and included inert placebos (n = 35). The majority of studies did not report on the integrity of blinding procedures (n = 34 studies); however, in studies that did, blinding was unsuccessful. Conclusion: To improve blinding and lower expectancy effects, we suggest incorporating active placebos and utilizing dose response or active comparator study designs.","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey","authors":"Brian S. Barnett, Miranda Arakelian, David Beebe, Jared Ontko, Connor Riegal, Willie O. Siu, Jeremy Weleff, Harrison G. Pope","doi":"10.1089/psymed.2023.0036","DOIUrl":"https://doi.org/10.1089/psymed.2023.0036","url":null,"abstract":"Background: Psilocybin, a classic hallucinogen, may eventually be approved by the United States Food and Drug Administration for treatment-resistant depression. However, we are aware of only one published national survey of American psychiatrists regarding their opinions about hallucinogens and hallucinogen-assisted therapy, conducted by our group in 2016. Here, we report a repeat survey, using virtually identical methods, assessing whether American psychiatrists display greater optimism about the therapeutic use of hallucinogens in 2022–23. Methods: We e-mailed our survey instrument to 1,000 randomly selected American Psychiatric Association members—250 resident-fellows and 750 attending psychiatrists—in late 2022 and early 2023. We calculated descriptive statistics and used a non-parametric trend test to compare the current survey responses with those from 2016. We also constructed a multivariate logistic regression model to assess attributes of respondents that predicted moderate/strong agreement with plans to incorporate hallucinogen-assisted therapy into their own practice. Results: The response rate was 13.1% (N = 131). Respondents were demographically similar to the 2016 respondents. A majority moderately/strongly believed that hallucinogens show promise in treating psychiatric conditions (80.9%) and substance use disorders (SUDs) (60.8%). Large majorities also moderately/strongly supported research into hallucinogens' therapeutic potential for psychiatric conditions (93.9%) and SUDs (88.6%), as well as federal funding of associated clinical trials (84.7% and 80.9%, respectively). Comparisons to 2016 showed significantly increased optimism regarding the therapeutic promise of hallucinogens and decreased concern about risks, with 50.4% of respondents reporting moderate/strong intentions to incorporate hallucinogen-assisted therapy into their practice. Conclusions: Our data reveal a striking positive shift in attitudes toward the therapeutic potential of hallucinogens among American psychiatrists since 2016, with a majority of responding psychiatrists planning to incorporate hallucinogen-assisted therapy into their practice if regulatory approval is granted.","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135010784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development","authors":"M. Weintraub, Jessica K. Jeffrey, Charles S. Grob, Megan C. Ichinose, R. L. Bergman, Ziva D. Cooper, D. Miklowitz","doi":"10.1089/psymed.2023.0018","DOIUrl":"https://doi.org/10.1089/psymed.2023.0018","url":null,"abstract":"","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75381245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applying Key Lessons from the Hospice and Palliative Care Movement to Inform Psychedelic-Assisted Therapy.","authors":"Megan Miller, William E Rosa, Alden Doerner Rinaldi, Katie Addicott, Dingle Spence, Yvan Beaussant","doi":"10.1089/psymed.2022.0009","DOIUrl":"10.1089/psymed.2022.0009","url":null,"abstract":"<p><strong>Background: </strong>Psychedelic-assisted therapy (PAT) has re-emerged as a promising intervention for addressing mental health conditions and existential concerns. Despite growing enthusiasm, PAT may be difficult to integrate into mainstream health systems. The rich sacramental traditions of psychedelics, their centering of the human experience, proposed substrates of action, context-dependent outcomes, and highly relational method of therapy all challenge dominant reductionistic approaches of the biomedical model. Hospice and palliative care are well established as holistic evidence-based standards of care, yet they began as a radical grassroots movement. Hospice and palliative care models may offer unique insights to support the growing field of PAT.</p><p><strong>Purpose: </strong>The intention of this commentary is to articulate the deep synergies between hospice and palliative care and PAT, with the intention of fostering interdisciplinary dialogue that may aid in implementation of human-centered high-quality PAT.</p><p><strong>Conclusions: </strong>Various aspects of hospice and palliative care models were identified and explored, which may support the implementation of human-centered high-quality PAT at scale. These include a focus on truly interdisciplinary care, applying a holistic lens to health and illness, bearing witness to suffering and healing, customized care, centering human relationships, decentralized models of care, generalist/specialist competencies, fostering spirituality, organizing as a social moment around shared goals, and growth from grassroots community organizations to mature care systems. Although hospice and palliative care can offer practical lessons for scaling human-centered experiential therapies, PAT, with its radical centering of meaning-making and relationship in the healing process, may also mutually innovate the fields of hospice and palliative care.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"1 3","pages":"124-129"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41159598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Elephant in the Room: Personal Use of Psychedelics Among Psychedelic Researchers","authors":"Peter S. Hendricks, Charles D. Nichols","doi":"10.1089/psymed.2023.29002.psh","DOIUrl":"https://doi.org/10.1089/psymed.2023.29002.psh","url":null,"abstract":"Psychedelic MedicineVol. 1, No. 3 EditorialFree AccessThe Elephant in the Room: Personal Use of Psychedelics Among Psychedelic ResearchersPeter S. Hendricks and Charles D. NicholsPeter S. Hendricks*Address correspondence to: Peter S. Hendricks, PhD, Department of Psychiatry and Behavioral Neurobiology, School of Medicine, University of Alabama at Birmingham, 530 Beacon Parkway West, Suite 702, Birmingham, AL 35209, USA, E-mail Address: [email protected]Department of Psychiatry and Behavioral Neurobiology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.Search for more papers by this author and Charles D. NicholsDepartment of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.Search for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/psymed.2023.29002.pshAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail In this issue, Pagán et al.1 report that among US medical students, personal use of psychedelics was associated with more positive attitudes toward psilocybin. More positive attitudes toward psilocybin were, in turn, associated with greater willingness to recommend psilocybin-assisted psychotherapy, if FDA approved. Herrmann et al.2 also found that psychiatric medication prescribers attributed improvements in depression, anxiety, and well-being to personal use of psychedelics. These two studies comport with a prior study in Psychedelic Medicine by Aday et al.,3 which found that almost 90% of the therapists associated with Usona Institute's Phase II clinical trial of psilocybin for major depressive disorder reported personal use of psychedelics. Collectively, this raises important questions around personal use of psychedelics among those conducting research (and in the anticipated future, clinical interventions) with these compounds.One question is whether personal use of psychedelics might play a role in the training of clinical research staff. This is not a novel idea. In 1957, when psychedelics were still thought of as psychotomimetics, the psychedelic pioneer Humphry Osmond wrote, “There is one golden rule that should be applied in working with model psychoses. One should start with oneself. Unless this is done, one cannot expect to make sense of someone else's communications and, consequently, the value of the work is greatly reduced.”4 Osmond's perspective was shared by other luminaries in the field including Albert Hofmann5 and Timothy Leary, Ralph Metzner, and Richard Alpert,6 and appears to have resonated with the scientific community. Indeed, personal use of psychedelics among psychedelic researchers in the 1950s through the early 1970s may have been commonplace, and it has been promoted by contemporary researchers with similar rationale.7And yet, whether personal use of psychedelics","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135349542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for <i>Psychedelic Medicine</i>","authors":"Jamie Peters","doi":"10.1089/psymed.2023.29001.rfs2022","DOIUrl":"https://doi.org/10.1089/psymed.2023.29001.rfs2022","url":null,"abstract":"Psychedelic MedicineVol. 1, No. 3 AnnouncementFree AccessRosalind Franklin Society Proudly Announces the 2022 Award Recipient for Psychedelic MedicineJamie PetersJamie PetersDepartment of Anesthesiology University of Colorado, Anschutz Medical Campus, Aurora, CO, USASearch for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/psymed.2023.29001.rfs2022AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail The Rosalind Franklin Society (RFS), in partnership with Mary Ann Liebert, Inc., publishers, enthusiastically congratulate our distinguished recipient of the 2022 annualRFS Award in Sciencefor this journal, which recognizes the outstanding research and published work of women and underrepresented minority scientists, physicians, and engineers.Jasper A. Heinsbrock, Giuseppe Gianotti, Joel Banilla, David E. Olson, and Jamie Peters. “Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model.” (June 2023): http://doi.org//10.1089/psymed.2023.0009AbstractThe potential use of psychedelic drugs as therapeutics for neuropsychiatric disorders has been limited by their hallucinogenic properties. To overcome this limitation, we developed tabernanthalog (TBG), a novel 5-HT2A agonist with reduced hallucinogenic potential. We previously demonstrated that TBG has therapeutic efficacy in a preclinical model of opioid use disorder in rats and separately in a binge model of alcohol drinking in mice. Alcohol is commonly co-used with opioids, yet preclinical models that recapitulate this comorbidity are lacking. We thus employed a polydrug model of heroin and alcohol co-use to screen the therapeutic efficacy of TBG on behavioral metrics of addiction. Whereas pre-exposure to alcohol in the home cage did not impact single-substance self-administration or relapse rates in this model, rats were subsequently allowed to co-self-administer heroin and alcohol. This allowed us to test the effects of TBG on motivation for each substance, measured as break points in a progressive ratio test, where the amount of effort required to obtain a single reward increases exponentially with each earned reward. TBG effectively reduced motivation for heroin and alcohol in this test, indicating its efficacy is preserved in animals with a history of heroin and alcohol polydrug use.BiosketchDr. Jamie Peters is an associate professor of anesthesiology at the University of Colorado Anschutz Medical Campus. Her research focuses on the neural circuits controlling drug-seeking behaviors, including circuits that promote addiction pathology, as well as those that limit it. Her work led to the identification of a neural circuit that functions as a limiter of drug seeking in preclinical rodent models of addiction. Dr. Peters has been searching for a common limiter circuit capable of diminishing a broad spectrum of addictive behavior","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135349543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda","authors":"Andrew D. Penn, R. Yehuda","doi":"10.1089/psymed.2023.0017","DOIUrl":"https://doi.org/10.1089/psymed.2023.0017","url":null,"abstract":"","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76247073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter?","authors":"Antonio F. Pagán, C. Lex, J. Soares, T. Meyer","doi":"10.1089/psymed.2023.0022","DOIUrl":"https://doi.org/10.1089/psymed.2023.0022","url":null,"abstract":"","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73178383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Therapeutic Alliance in Psychedelic-Assisted Psychotherapy: A Novel Target for Research and Interventions","authors":"Philip Kamilar-Britt, E. Gordis, M. Earleywine","doi":"10.1089/psymed.2023.0020","DOIUrl":"https://doi.org/10.1089/psymed.2023.0020","url":null,"abstract":"","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"258 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75765591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}